On March 22, 2021 INmune Bio, Inc. (NASDAQ: INMB) (the, "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, reported that Professor Mark Lowdell, PhD, Chief Scientific Officer of INmune Bio, will deliver presentations at two upcoming medical meetings (Press release, INmune Bio, MAR 22, 2021, View Source [SID1234576997]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Event details:
Innate Killer Digital Summit 2021, March 23-25
Title: Exploring the Network of Cellular Interactions of NK Cells in the Tumor Microenvironment
Date: Thursday, March 25
Time: 3:30 EDT
In this presentation, Dr. Lowdell will discuss the company’s latest data and the discovery of a new mechanism of action of its NK-priming immunotherapy, "INKmune". INKmune is a clinical stage proprietary tumor cell line which is administered intravenously and primes NK cells to kill otherwise resistant tumors. INKmune-primed NK cells have been shown to kill a wide variety of solid and hematological cancer cells in preclinical studies.
Use of two of the latest state-of-the-art cell:cell analysis technologies has demonstrated that INKmune increases NK cell killing of tumor cells by strengthening the binding of the NK to the tumor cell; the avidity. Our preclinical studies show that the robust immune synapse created by INKmune priming is greater than that induced by conventional cytokine activation (IL-2 or IL-15) and allows more rapid NK-mediated killing which was confirmed by videomicrography. These INKmune-primed NK cells are not only more efficient killers of tumor cells but are able to overcome inhibition by regulatory cells and hypoxia in the tumor microenvironment.
Additional information about the summit, including registration details, can be found at: View Source
Festival of Biologics USA: World Immunotherapy Congress 2021, March 29-April 1
Session: Cell and Gene Therapy
Title: Enhancing the Cellular Interactions Between NK Cells and Tumor Cells
Date: Monday, March 29
Time: 11:00am EDT
This second presentation will focus on the immunobiology of the NK:tumor immune synapse and the impact of tumor cell susceptibility to NK killing on NK exhaustion and the ability to lyse multiple target cells.
Additional information can be found at: View Source
About INKmune
INKmune is an experimental biologic undergoing clinical trials that is a pharmaceutical-grade, replication incompetent tumor cell that delivers essential priming signals to patients’ resting NK cells. INKmune is delivered by IV infusion. Once in the patient’s system, INKmune comes in contact with resting NK cells. The interaction converts NK cells to "primed NK cell" (pNK) similar to an "on-off" switch. pNK then remain primed until they contact and kill cancer cells. INKmune-primed NK cells have a mRNA fingerprint which is fundamentally different to NK cells activated with IL-2 or IL-15.